Biological variation for N-terminal pro- and B-type natriuretic peptides and implications for therapeutic monitoring of patients with congestive heart failure.
Given the limitations of low enrollments, this study suggests that a change of 130% for B-type natiuretic peptide (BNP) and 90% for N-terminal (NT)-proBNP are necessary before results of serially collected data can be considered statistically different. This study also shows that there are important differences in the performance of BNP versus NT-proBNP in monitoring patients with congestive heart failure that need to be further explored.
Wu
Alan H B
AH
Department of Pathology and Laboratory Medicine, Hartford Hospital, Hartford, Connecticut 06102, USA. awu@harthosp.org
Smith
Andrew
A
Wieczorek
Stacey
S
Mather
Jeffrey F
JF
Duncan
Bret
B
White
C Michael
CM
McGill
Carol
C
Katten
Deb
D
Heller
Gary
G
D000328:Adult; D000704:Analysis of Variance; D009320:Atrial Natriuretic Factor / Q000097:blood*; D015415:Biomarkers / Q000097:blood; D016022:Case-Control Studies; D016002:Discriminant Analysis; D016903:Drug Monitoring / Q000379:methods* / Q000592:standards; D005260:Female; D006333:Heart Failure / Q000097:blood* / Q000145:classification / Q000175:diagnosis / Q000188:drug therapy; D006801:Humans; D007118:Immunoassay / Q000379:methods / Q000592:standards; D008297:Male; D008875:Middle Aged; D020097:Natriuretic Peptide, Brain; D015588:Observer Variation; D010865:Pilot Projects; D019095:Point-of-Care Systems / Q000592:standards; D011498:Protein Precursors / Q000097:blood*; D011863:Radioimmunoassay / Q000379:methods / Q000592:standards; D012016:Reference Values; D012680:Sensitivity and Specificity; D012720:Severity of Illness Index; D013997:Time Factors
D015415:Biomarkers; C099254:N-terminal proatrial natriuretic peptide; D011498:Protein Precursors; D020097:Natriuretic Peptide, Brain; D009320:Atrial Natriuretic Factor